
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Japan's Meiji Seika Pharma collaborates with MBC BioLabs for global innovation in drug discovery

December 19, 2025 | News

To discover innovative drug discovery seeds and to accelerate external collaborations



Japan-based Meiji Seika Pharma has entered into a partnership agreement with MBC BioLabs which is a private organisation supporting the development of biotech startup companies in California's San Francisco Bay Area.

MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization.

Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover innovative drug discovery seeds and to accelerate external collaborations.

"We aim to energise our drug discovery research by drawing new ideas from global innovation activities and deepening collaboration with innovation hubs in Japan and overseas. Partnering with MBC BioLabs, which has a proven track record of identifying numerous startups and guiding them toward commercialization, represents a major step forward in these efforts," said Takeshi Naruse, Managing Executive Officer and Head of R&D at Meiji Seika Pharma.